Blue Jet Healthcare Limited (BSE: 544009, NSE: BLUEJET) has taken a significant step towards expanding its manufacturing capabilities with the acquisition of a substantial land parcel in Andhra Pradesh. The company's Board of Directors has approved the acquisition of 102.48 acres of industrial land in the Anakapalli District, setting the stage for a new state-of-the-art manufacturing facility.

Land Acquisition Details

The company received an allotment letter from the Andhra Pradesh Industrial Infrastructure Corporation Ltd (APIIC) for the land located at Industrial Park Rambilli Cluster Phase II. This allotment is based on G.O.Ms.No.82 dated May 23, 2025, issued by the Government of Andhra Pradesh under the State's Industrial Policy (4.0).

Financial Implications

The land acquisition comes at a cost of INR 41.87 crores. However, the company's investment plans go far beyond the initial land purchase:

• Phase I Investment: BlueJet Healthcare estimates a capital investment of up to INR 1,000.00 crores for the first phase of development.
• Deployment Strategy: The investment will be deployed in a modular manner, allowing for scalable growth.
• Financing Options: The company plans to finance this ambitious project through a combination of internal accruals, equity, and debt.

Expansion Plans and Capacity

The new facility is part of BlueJet Healthcare's long-term capacity expansion strategy, aimed at supporting growth, enabling entry into new product verticals, and strengthening strategic relationships. Key details of the expansion include:

• Proposed Capacity: Phase I will add up to 1,000 KL of manufacturing capacity.
• Scalability: The facility is designed to be scalable in subsequent phases.
• Commissioning Target: The company aims to have the facility operational by FY 2028-29.

Strategic Rationale

This greenfield project aligns with BlueJet Healthcare's business objectives and demand outlook across key therapeutic platforms. The company sees this expansion as crucial for:

1. Supporting its growth trajectory through forward-looking capacity creation.
2. Enabling entry into new product verticals.
3. Deepening strategic relationships in the pharmaceutical industry.

Corporate Governance

The decision was made during a Board of Directors meeting held on July 31, 2025. The meeting commenced at 2:00 P.M. and concluded at 2:22 P.M., demonstrating the company's commitment to transparent and timely disclosure of material information to its stakeholders.

BlueJet Healthcare's ambitious expansion plan reflects the company's confidence in its growth prospects and its commitment to strengthening its position in the pharmaceutical manufacturing sector. As the project unfolds, investors and industry watchers will be keen to see how this significant investment translates into enhanced capabilities and market presence for the company.

Blue Jet Healthcare Limited (BSE: 544009, NSE: BLUEJET) has taken a significant step towards expanding its manufacturing capabilities by acquiring a substantial land parcel in Andhra Pradesh. The company's Board of Directors has approved the acquisition of 102.48 acres of industrial land in the Anakapalli District, marking a major milestone in its long-term growth strategy.

Land Acquisition Details

The pharmaceutical company received an allotment letter from the Andhra Pradesh Industrial Infrastructure Corporation Ltd (APIIC) for the land located at Industrial Park Rambilli Cluster Phase II. The acquisition comes at a cost of INR 41.87 crore, as disclosed in the company's regulatory filing.

Planned Investment and Capacity Expansion

Blue Jet Healthcare has outlined an ambitious plan for the newly acquired land:

• Phase I Investment: The company estimates a capital investment of up to INR 1,000 crore for the initial phase.
• Capacity Addition: The proposed facility will add a manufacturing capacity of up to 1,000 KL in Phase I, with plans for scalability in subsequent phases.
• Commissioning Timeline: The new facility is targeted to be operational by FY 2028-29.

Strategic Importance

This greenfield project is a crucial component of Blue Jet Healthcare's long-term capacity expansion strategy. The company aims to:

1. Support its growth trajectory
2. Enable entry into new product verticals
3. Strengthen strategic relationships within the industry

Financing the Project

The company plans to finance this significant expansion through various means, including:

• Internal accruals
• Equity
• Debt

Regulatory Compliance

The land allotment is in accordance with G.O.Ms.No.82 dated May 23, 2025, issued by the Government of Andhra Pradesh under the State's Industrial Policy (4.0). Blue Jet Healthcare made the announcement in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Looking Ahead

As Blue Jet Healthcare embarks on this expansive project, the pharmaceutical industry will be watching closely. The substantial investment and capacity addition signal the company's confidence in future demand across key therapeutic platforms. With the facility set to be commissioned by FY 2028-29, Blue Jet Healthcare is positioning itself for significant growth and increased market presence in the coming years.

Investors and industry observers will likely keep a close eye on the progress of this project, as it represents a major commitment to expanding Blue Jet Healthcare's manufacturing capabilities and potentially its market share in the pharmaceutical sector.